Citi analyst Yigal Nochomovitz lowered the firm’s price target on Applied Therapeutics (APLT) to $8 from $13 and keeps a Buy rating on the shares, calling the Complete Response Letter received from the FDA for govorestat in galactosemia a “head-scratcher.” It appears the FDA could not get past the missed primary endpoint given full approval was at stake, says the analyst, who is now lowering the firm’s view on the odds of success in galactosemia to 50% given the CRL news. However, the firm argues that the SORD program alone, which is independent and being reviewed by Neurology I under accelerated approval, is worth $6 per share, so a Buy rating is “still warranted.” The analyst also removed the “90-day positive catalyst watch” that the firm previously had placed on the shares.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLT:
- Applied Therapeutics price target lowered to $5 from $14 at Baird
- Unusually active option classes on open November 29th
- Voyager upgraded, HP downgraded: Wall Street’s top analyst calls
- Voyager rises after upgrade, Applied plunges after CRL: Morning Movers
- Applied Therapeutics CRL a ‘major setback,’ says William Blair
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
